Unknown

Dataset Information

0

Risk factors for clinically significant diffuse parenchymal lung abnormalities persisting after severe COVID-19 pneumonia.


ABSTRACT:

Background & objectives

The risk factors for clinically significant diffuse parenchymal lung abnormalities (CS-DPLA) persisting after severe coronavirus disease 2019 (COVID-19) pneumonia remain unclear. The present study was conducted to assess whether COVID-19 severity and other parameters are associated with CS-DPLA.

Methods

The study participants included patients who recovered after acute severe COVID-19 and presented with CS-DPLA at two or six month follow up and control group (without CS-DPLA). Adults volunteers without any acute illness, chronic respiratory illness and without a history of severe COVID-19 were included as healthy controls for the biomarker study. The CS-DPLA was identified as a multidimensional entity involving clinical, radiological and physiological pulmonary abnormalities. The primary exposure was the neutrophil-lymphocyte ratio (NLR). Recorded confounders included age, sex, peak lactate dehydrogenase (LDH), advanced respiratory support (ARS), length of hospital stay (LOS) and others; associations were analyzed using logistic regression. The baseline serum levels of surfactant protein D, cancer antigen 15-3 and transforming growth factor-β (TGF-β) were also compared among cases, controls and healthy volunteers.

Results

We identified 91/160 (56.9%) and 42/144 (29.2%) participants with CS-DPLA at two and six months, respectively. Univariate analyses revealed associations of NLR, peak LDH, ARS and LOS with CS-DPLA at two months and of NLR and LOS at six months. The NLR was not independently associated with CS-DPLA at either visit. Only LOS independently predicted CS-DPLA at two months [adjusted odds ratios (aOR) (95% confidence interval [CI]), 1.16 (1.07-1.25); P<0.001] and six months [aOR (95% CI) and 1.07 (1.01-1.12); P=0.01]. Participants with CS-DPLA at six months had higher baseline serum TGF-β levels than healthy volunteers.

Interpretation and conclusions

Longer hospital stay was observed to be the only independent predictor of CS-DPLA six months after severe COVID-19. Serum TGF-β should be evaluated further as a biomarker.

SUBMITTER: Dhooria S 

PROVIDER: S-EPMC10443720 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background & objectives</h4>The risk factors for clinically significant diffuse parenchymal lung abnormalities (CS-DPLA) persisting after severe coronavirus disease 2019 (COVID-19) pneumonia remain unclear. The present study was conducted to assess whether COVID-19 severity and other parameters are associated with CS-DPLA.<h4>Methods</h4>The study participants included patients who recovered after acute severe COVID-19 and presented with CS-DPLA at two or six month follow up and control grou  ...[more]

Similar Datasets

| S-EPMC9489187 | biostudies-literature
| S-EPMC4351573 | biostudies-literature
| S-EPMC3968138 | biostudies-literature
| S-EPMC3489730 | biostudies-literature
| S-EPMC8950114 | biostudies-literature
| S-EPMC7814131 | biostudies-literature
| S-EPMC9981527 | biostudies-literature
| S-EPMC5415669 | biostudies-literature
| S-EPMC9538882 | biostudies-literature